Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDORA-switch adalimumab concentration-guided biologic switching in rheumatoid arthritis
NL-OMON52747Recruiting
- Sponsor
- Reade
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of adalimumab, etanercept, infliximab, golimumab, certolizumab pegol and 8 more in rheumatoid arthritis (RA), sponsored by Reade. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON52747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52747.